Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice
Executive Summary
The TRK inhibitor won over ASCO with deep and durable responses across 17 cancer types, but diagnostics will be the true test of the tumor-agnostic approach – and the focus of Loxo's commercial strategy.
You may also be interested in...
ASCO 2018: Optimism As Industry Resets And Looks To What Is Next
Investors weren't wildy impressed by the data at ASCO this year, but for pharma, the meeting felt like a renewal, a recommitment to getting it right. It was more a year of refinement as industry digests the advances that have been made, the big mistakes, and pivots toward where to go next.
Loxo Edges Closer To Commercial Market With Larotrectinib, But Diagnostic Challenge Persists
Loxo impressed at ASCO last year with larotrectinib, which has now been accepted by FDA for priority review with a PDUFA date of Nov. 26, and the oncology drug developer could shine again this year. If approved, however, larotrectinib could launch ahead of its companion diagnostic.
Other ASCO 2018 Highlights – It’s Not All IO
The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.